MBX Biosciences, Inc. (NASDAQ:MBX - Free Report) - Stock analysts at HC Wainwright issued their FY2026 earnings per share (EPS) estimates for MBX Biosciences in a report issued on Thursday, November 12th. HC Wainwright analyst M. Kapoor expects that the company will earn ($3.13) per share for the year. HC Wainwright currently has a "Buy" rating and a $90.00 target price on the stock. The consensus estimate for MBX Biosciences' current full-year earnings is ($3.42) per share. HC Wainwright also issued estimates for MBX Biosciences' Q4 2026 earnings at ($1.00) EPS, Q1 2027 earnings at ($1.01) EPS, Q2 2027 earnings at ($1.08) EPS, Q3 2027 earnings at ($1.12) EPS, Q4 2027 earnings at ($1.16) EPS and FY2027 earnings at ($4.37) EPS.
MBX Biosciences (NASDAQ:MBX - Get Free Report) last posted its earnings results on Monday, November 9th. The company reported ($1.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.49).
MBX has been the topic of a number of other research reports. JPMorgan Chase & Co. initiated coverage on shares of MBX Biosciences in a research note on Friday, August 21st. They set an "overweight" rating and a $88.00 price objective on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of MBX Biosciences in a research note on Thursday, October 15th. Wall Street Zen lowered shares of MBX Biosciences from a "hold" rating to a "sell" rating in a report on Saturday, August 8th. Barclays reaffirmed an "overweight" rating and set a $88.00 price target on shares of MBX Biosciences in a report on Friday, August 7th. Finally, Truist Financial lifted their price target on shares of MBX Biosciences from $70.00 to $88.00 and gave the stock a "buy" rating in a research note on Monday, August 10th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $87.30.
Get Our Latest Report on MBX Biosciences
MBX Biosciences Price Performance
NASDAQ MBX opened at $55.94 on Monday. MBX Biosciences has a fifty-two week low of $23.07 and a fifty-two week high of $72.64. The business has a 50 day moving average price of $55.78 and a two-hundred day moving average price of $46.39. The stock has a market cap of $2.78 billion, a PE ratio of -18.22 and a beta of 0.18.
Insiders Place Their Bets
In other MBX Biosciences news, CEO Steven Hoerter sold 4,893 shares of the firm's stock in a transaction that occurred on Tuesday, November 10th. The stock was sold at an average price of $54.82, for a total transaction of $268,234.26. Following the completion of the sale, the chief executive officer owned 78,045 shares in the company, valued at $4,278,426.90. This trade represents a 5.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 31.09% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On MBX Biosciences
Institutional investors and hedge funds have recently made changes to their positions in the business. Wellington Management Group LLP increased its stake in shares of MBX Biosciences by 55.9% in the second quarter. Wellington Management Group LLP now owns 4,977,523 shares of the company's stock worth $274,759,000 after buying an additional 1,785,699 shares during the last quarter. BlackRock Inc. bought a new position in MBX Biosciences during the 2nd quarter valued at $183,467,000. Parkman Healthcare Partners LLC bought a new position in MBX Biosciences during the 2nd quarter valued at $44,170,000. Bank of America Corp DE acquired a new position in MBX Biosciences during the 2nd quarter worth $16,501,000. Finally, Stempoint Capital LP grew its holdings in MBX Biosciences by 535.8% during the 1st quarter. Stempoint Capital LP now owns 499,469 shares of the company's stock worth $14,909,000 after acquiring an additional 420,916 shares in the last quarter.
Key Stories Impacting MBX Biosciences
Here are a few of the latest stories about MBX:
- Positive Sentiment: Oppenheimer initiated or reiterated a Buy rating on MBX, adding to favorable analyst sentiment. Oppenheimer Buy rating
- Neutral Sentiment: CEO Steven Hoerter sold 4,893 shares for about $268,000, but the filing said the sale covered tax withholding on vested equity awards. He retained 78,045 shares, making the transaction less concerning than a discretionary sale. CEO share sale
- Negative Sentiment: MBX reported a quarterly loss of $1.29 per share, wider than analysts’ expected loss of $0.80, a headwind that contrasts with the upbeat analyst ratings.
MBX Biosciences Company Profile
(
Get Free Report)
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company developing peptide-based treatments for endocrine and metabolic disorders. The company's research focuses on conditions in which naturally occurring hormones are deficient or do not function adequately. MBX uses its Precision Endocrine Peptide (PEP) platform to design peptide medicines intended to provide more durable hormone activity. Its lead candidate, MBX 2109, is being developed as a long-acting parathyroid hormone replacement therapy for people with chronic hypoparathyroidism.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider MBX Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MBX Biosciences wasn't on the list.
While MBX Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.